Cardioplegic

Cardioplegic solution with added sodium bicarbonate when cooled and instilled into the coronary artery vasculature, causes prompt arrest of cardiac electromechanical activity, combats intracellular ion losses and buffers ischemic acidosis. When used with hypothermia and ischemia, the action may be characterized as cold ischemic potassium-induced cardioplegia.

This is conducive to providing the surgeon with a quiet, relaxed heart and bloodless field of operation.

Calcium (Ca++) ion in low concentration is included in the solution to maintain integrity of cell membrane to ensure that there is no likelihood of calcium paradox during reperfusion.

Magnesium (Mg++) ion may help stabilize the myocardial membrane by inhibiting a myosin phosphorylase, which protects adenosine triphosphate (ATP) reserves for postischemic activity. The protective effects of magnesium and potassium have been shown to be additive.

Potassium (K+) ion concentration is responsible for prompt cessation of mechanical myocardial contractile activity. The immediacy of the arrest thus preserves energy supplies for postischemic contractile activity in diastole.

The chloride (Cl-) and sodium (Na+) ions have no specific role in the production of cardiac arrest. Sodium is essential to maintain ionic integrity of myocardial tissue. The chloride ions are present to maintain the electroneutrality of the solution.

Added bicarbonate (HCO3-) anion is included as a buffer to render the solution slightly alkaline and compensate for the metabolic acidosis that accompanies ischemia.

Extemporaneous alternative buffering to the described formulation of this solution is not recommended.

Baxter Cardioplegic Solution must not be administered without the addition of 8.4% Sodium Bicarbonate Injection, USP, Hospira1 List 4900.

NOT FOR INTRAVENOUS INJECTION.

This solution is only for instillation into cardiac vasculature after buffering with sodium bicarbonate.

Overzealous instillation of the solution may result in unnecessary dilatation of the myocardial vasculature and leakage into the perivascular myocardium, possibly causing tissue edema. (See WARNINGS, PRECAUTIONS, and ADVERSE REACTIONS.)

The following information is suggested as a guide and is subject to variation according to the preference and experience of the surgeon. It is required that 10 mL (840 mg) of 8.4% Sodium Bicarbonate Injection, USP (10 mEq each of sodium and bicarbonate) be added aseptically and thoroughly mixed with each 1000 mL of Cardioplegic solution to adjust pH. Use 10 mL of Hospira1 List 4900, 8.4% Sodium Bicarbonate Injection, USP, to achieve the approximate pH of 7.8 when measured at room temperature. Use of any other Sodium Bicarbonate Injection may not achieve this pH due to the varying pH’s of Sodium Bicarbonate Injections. Due to its inherent instability with other components, sodium bicarbonate must be added just prior to administration. After this addition, the solution must be used within 24 hours. The solution should be cooled to 4°C prior to use. Following institution of cardiopulmonary bypass at perfusate temperatures of 28° to 30°C, and after cross-clamping of the ascending aorta, the buffered solution is administered by rapid infusion into the aortic root. The initial rate of infusion may be 300 mL/m2/minute (about 540 mL/min in a 5’ 8”, 70 kg adult with 1.8 square meters of surface area) given for a period of two to four minutes. Concurrent external cooling (regional hypothermia of the pericardium) may be accomplished by instilling a refrigerated (4°C) physiologic solution such as a Normosol®2 -R (balanced electrolyte replacement solution) or Ringer's Injection into the chest cavity.

Should myocardial electromechanical activity persist or recur, the solution may be reinfused at a rate of 300 mL/m2/min for a period of two minutes. Reinfusion of the solution may be repeated every 20 to 30 minutes or sooner if myocardial temperature rises above 15° to 20°C or returning cardiac activity is observed. The regional hypothermia solution around the heart also may be replenished continuously or periodically in order to maintain adequate hypothermia. Suction may be used to remove warmed infusates. An implanted thermistor probe may be used to monitor myocardial temperature.

The volumes of solution instilled into the aortic root may vary depending on the duration or type of open heart surgical procedure.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. (See PRECAUTIONS.)

Baxter Cardioplegic Solution is supplied (without sodium bicarbonate) in a single-dose 1000 mL flexible plastic container as follows:

2B1462          NDC 0338-0341-04

WARNING: Do not use flexible container in series connections.

Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. Protect from freezing. It is recommended that the product be stored at room temperature (25°C); however, brief exposure up to 40°C does not adversely affect the product.

For Product Information
Call 1-800-933-0303

Baxter Healthcare Corporation
Deerfield, IL 60015 USA

Printed in USA

07-19-73-074

Rev. June 2014

Baxter and PL146 are trademarks of Baxter International Inc.
1Hospira, Inc., Lake Forest, IL 60045 USA
2Normosol® is a trademark of Hospira, Inc.

Container Label

Container Label

LOT
EXP

2B1462

NDC 0338-0341-04

Cardioplegic Solution
FOR CARDIAC PERFUSION

W A R N I N G :
NOT FOR INTRAVENOUS
INJECTION

CAUTION USE ASEPTIC TECHNIQUE ADDITION OF 10 ML OF
8.4% SODIUM BICARBONATE INJECTION USP
ABBOTT LIST 4900 IS REQUIRED PRIOR TO USAGE TO
ADJUST THE pH TO APPROXIMATELY 7.8 AT ROOM
TEMPERATURE (SEE INSERT) MIX THOROUGHLY
AFFIX ADDITIVE LABEL OVER LABEL ON FLEXIBLE CONTAINER

1000 mL
EACH 100 mL CONTAINS SODIUM CHLORIDE USP 643 mg
MAGNESIUM CHLORIDE HEXAHYDRATE USP 325.3 mg
POTASSIUM CHLORIDE USP 119.3 mg CALCIUM CHLORIDE
DIHYDRATE USP 17.6 mg MAY CONTAIN HCI AND/OR NAOH FOR pH
ADJUSTMENT 304 mOsmol/L (CALC) pH 3.8 (3.5-3.9) PRIOR TO
SODIUM BICARBONATE ADDITION ELECTROLYTES PER 1000 mL (NOT
INCLUDING IONS FOR pH ADJUSTMENT) SODIUM 110 mEq
MAGNESIUM 32 mEq POTASSIUM 16 mEq CALCIUM 2.4 mEq
CHLORIDE 160 mEq STERILE NONPYROGENIC

DO NOT REMOVE FROM OVERWRAP UNTIL READY FOR USE

AFTER REMOVING THE OVERWRAP CHECK FOR MINUTE LEAKS BY
SQUEEZING CONTAINER FIRMLY IF LEAKS ARE FOUND DISCARD SOLUTION
AS STERILITY MAY BE IMPAIRED RECOMMENDED STORAGE ROOM
TEMPERATURE (25°C) AVOID EXCESSIVE HEAT PROTECT FROM
FREEZING STORE SOLUTION CONTAINING BICARBONATE UNDER
REFRIGERATION DO NOT STORE LONGER THAN 24 HOURS ADDITIVES
MAY BE INCOMPATIBLE CONSULT WITH PHARMACIST IF AVAILABLE
WHEN INTRODUCING ADDITIVES USE ASEPTIC TECHNIQUE
MIX THOROUGHLY AND DO NOT STORE USE ONLY IF SOLUTION IS CLEAR
AND CONTAINER IS UNDAMAGED USUAL DOSAGE SEE INSERT
MUST NOT BE USED IN SERIES CONNECTIONS

Rx ONLY

VIAFLEX CONTAINER PL 146 PLASTIC

BAXTER VIAFLEX AND PL 146 ARE TRADEMARKS
OF BAXTER INTERNATIONAL INC

Baxter logo
BAXTER HEALTHCARE CORPORATION
DEERFIELD IL 60015 USA

MADE IN USA

FOR PRODUCT INFORMATION

1-800-933-0303

Carton Label - panel 1

Carton Label - panel 1

2B1462X
Cardioplegic SOLUTION

14-1000 ML

Viaflex container
Protect from freezing

BAR CODE
(01)50303380341042
(21)NNNNNNNNN
(17)YYMMDD
(10)XXXXXXX

EXP YYYY-MM-DD
LOT XXXXXXX

BAR CODE
(01)50303380341042 (21)NNNNNNNNN (17)YYMMDD (10) XXXXXXX

Carton Label – panel 2

2B1462X
Cardioplegic SOLUTION

14 – 1000 ML

Viaflex container
Protect from freezing

EXP YYYY-MM-DD